Literature DB >> 16690006

Differential physiological effects of a low dose and high doses of venlafaxine in major depression.

Guy Debonnel1, Elise Saint-André, Chantal Hébert, Claude de Montigny, Normand Lavoie, Pierre Blier.   

Abstract

Venlafaxine is an antidepressant drug with demonstrated serotonin (5-HT) and norepinephrine (NE) reuptake blockade properties in electrophysiological and microdialysis experiments in laboratory animals. In healthy volunteers, its 5-HT reuptake-inhibiting potential has also been clearly documented, but not its NE reuptake blockade action. This double-blind study compared the effects of a low dose (75 mg) and of a forced titration of high (up to 375 mg in 1 wk) daily doses of venlafaxine. Forty-four patients with major depression according to DSM-IV criteria were assessed bi-weekly for the first 2 wk and weekly for the next 2 wk. Inhibition of 5-HT reuptake was estimated using the depletion of whole-blood 5-HT, while that of NE was assessed using the attenuation of the systolic blood-pressure elevations produced by intravenous injections of tyramine. Forty-two patients completed the study. Both the low and the high doses of venlafaxine decreased the levels of 5-HT to the same extent: the reduction was of about 55% after 1 wk and of 75% after 4 wk. The 75 mg/d dose of venlafaxine did not alter the tyramine pressor response, whereas, in patients receiving the higher regimens of venlafaxine, there was a significant attenuation of the pressor effect of tyramine. There was no significant difference between the two treatment arms regarding the modifications of the depression scores. The present data showed that, at its minimal effective dose in depression (75 mg/d), venlafaxine acted as a selective 5-HT reuptake inhibitor, whereas when administered at higher doses (225 and 375 mg/d), it acted as a dual 5-HT and NE reuptake inhibitor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690006     DOI: 10.1017/S1461145705006413

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  28 in total

1.  Addressing both depression and pain in late life: the methodology of the ADAPT study.

Authors:  Jordan F Karp; Bruce L Rollman; Charles F Reynolds; Jennifer Q Morse; Frank Lotrich; Sati Mazumdar; Natalia Morone; Debra K Weiner
Journal:  Pain Med       Date:  2012-02-07       Impact factor: 3.750

2.  Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635.

Authors:  Eydie L Moses-Kolko; Julie C Price; Michael E Thase; Carolyn Cidis Meltzer; David J Kupfer; Chester A Mathis; Wendy D Bogers; Susan R Berman; Patricia R Houck; Trisha N Schneider; Wayne C Drevets
Journal:  Synapse       Date:  2007-07       Impact factor: 2.562

3.  The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks.

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2007-07       Impact factor: 6.186

4.  Alleviation of hot flashes with increase in venlafaxine dose.

Authors:  Prasad R Padala; Srinivas B Rapuri; Kalpana P Padala
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 5.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

6.  Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion.

Authors:  Ramez Ghanbari; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2011-03-29       Impact factor: 4.530

7.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

8.  Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.

Authors:  Daniel Z Lieberman; Suena H Massey
Journal:  Core Evid       Date:  2010-06-15

9.  Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.

Authors:  David V Sheehan; Matthew S Keene; Michael Eaddy; Stan Krulewicz; John E Kraus; David J Carpenter
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors.

Authors:  Corine Ekhart; Florence van Hunsel; Joep Scholl; Sieta de Vries; Eugene van Puijenbroek
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.